Literature DB >> 12395887

Lower th-1/th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C.

Naohiko Masaki1, Sugano Fukushima, Shigeki Hayashi.   

Abstract

It is still controversial whether alterations in helper-T cell subpopulations contribute to the pathogenesis and clinical characteristics of chronic hepatitis C. The aim of this study was to clarify this issue, particularly in relation to interferon therapy. Thirty-one patients with histologically proven chronic hepatitis C were treated by conventional interferon (IFN) monotherapy for 6 months, and virological responses were evaluated by polymerase chain reaction 6 months later. Helper-T cell subpopulations, Th-1 and Th-2, were determined in peripheral blood by intracellular cytokine assay using flow cytometry. In chronic hepatitis C, the percentage of Th-1 and Th-2 subpopulations in peripheral blood were significantly increased, by 1.4-fold as compared with normal controls. Serum levels of ALT were inversely proportional to the percentage of Th-1 subpopulations, while directly proportional to that of Th-2 subpopulations. In nonresponders (N = 16) to interferon therapy, the percentage of Th-1 subpopulations and Th-1/Th-2 ratio were significantly higher than those in complete responders (N = 15). By multivariate logistic regression analysis, HCV genotype non-lb, HCV viral load less than 500 kilocopies/ml, and the lower Th-1/Th-2 ratio could independently merit favorable long-term virological responses. Helper-T cell subpopulations, Th-1 and Th-2, seem to contribute to progression of chronic hepatitis C in a reciprocal fashion. The imbalance between the two subpopulations may determine the final outcome of interferon therapy as one of the host factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12395887     DOI: 10.1023/a:1020114722763

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection.

Authors:  Y Kawakami; S Nabeshima; N Furusyo; Y Sawayama; J Hayashi; S Kashiwagi
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

2.  Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.

Authors:  K Chayama; A Tsubota; M Kobayashi; K Okamoto; M Hashimoto; Y Miyano; H Koike; M Kobayashi; I Koida; Y Arase; S Saitoh; Y Suzuki; N Murashima; K Ikeda; H Kumada
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

3.  Predictive factors in the response to interferon therapy in chronic hepatitis C.

Authors:  K Yoshioka; Y Higashi; M Yamada; T Aiyama; M Takayanagi; K Tanaka; A Okumura; K Iwata; S Kakumu
Journal:  Liver       Date:  1995-04

4.  Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection.

Authors:  L J Yee; J Tang; A W Gibson; R Kimberly; D J Van Leeuwen; R A Kaslow
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

5.  In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: failure in IL-2 production despite proliferation.

Authors:  D D Eckels; N Tabatabail; T H Bian; H Wang; S S Muheisen; C M Rice; K Yoshizawa; J Gill
Journal:  Hum Immunol       Date:  1999-03       Impact factor: 2.850

6.  The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.

Authors:  M Shindo; K Arai; T Okuno
Journal:  J Hepatol       Date:  1997-03       Impact factor: 25.083

7.  Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

Authors:  M Martinot-Peignoux; P Marcellin; M Pouteau; C Castelnau; N Boyer; M Poliquin; C Degott; I Descombes; V Le Breton; V Milotova
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

8.  In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice.

Authors:  D Healey; P Ozegbe; S Arden; P Chandler; J Hutton; A Cooke
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

9.  CD4+ subset regulation in viral infection. Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice.

Authors:  R T Gazzinelli; M Makino; S K Chattopadhyay; C M Snapper; A Sher; A W Hügin; H C Morse
Journal:  J Immunol       Date:  1992-01-01       Impact factor: 5.422

10.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

View more
  6 in total

1.  Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.

Authors:  F Torre; S Rossol; N Pelli; M Basso; A Delfino; A Picciotto
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

2.  Effects of HCV treatment on cytokine expression during HCV/HIV coinfection.

Authors:  Jason T Blackard; Minhee Kang; Kenneth E Sherman; Margaret James Koziel; Marion G Peters; Raymond T Chung
Journal:  J Interferon Cytokine Res       Date:  2006-11       Impact factor: 2.607

3.  Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4(+) T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load.

Authors:  Koji Ishii; Mie Shinohara; Michio Kogame; Misato Shiratori; Katsuya Higami; Kaori Kanayama; Kazue Shiozawa; Noritaka Wakui; Hidenari Nagai; Manabu Watanabe; Yasukiyo Sumino
Journal:  Hepatol Int       Date:  2011-08-06       Impact factor: 6.047

4.  Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders.

Authors:  Toshio Ariyasu; Takeshi Tanaka; Noboru Fujioka; Yoshiaki Yanai; Shigeto Yamamoto; Hiroshi Yamauchi; Hakuo Ikegami; Masao Ikeda; Masashi Kurimoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 Jan-Feb       Impact factor: 2.416

5.  Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C.

Authors:  Anatol Panasiuk; Danuta Prokopowicz; Bozena Panasiuk
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

6.  On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula.

Authors:  Hidetsugu Saito; Hirotoshi Ebinuma; Keisuke Ojiro; Kanji Wakabayashi; Mika Inoue; Shinichiro Tada; Toshifumi Hibi
Journal:  World J Gastroenterol       Date:  2010-01-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.